The FDA approved Bausch + Lomb’s Lumify as the first over-the-counter eye drop developed with low-dose brimonidine tartrate for the treatment of ocular redness.
Brimonidine was first approved by the FDA in 1996 for the reduction of IOP in glaucoma patients, according to a press release from Valeant Pharmaceuticals.
“Lumify is the first and only OTC eye drop with low-dose brimonidine, which has been clinically proven to be safe and effective since its initial approval as a prescription medication in 1996,” Joseph C. Papa, chairman and CEO of Valeant, said in the release.
Lumify (brimonidine tartrate ophthalmic solution 0.025%) is expected to be available in the second quarter of 2018.
Frequent use of non-selective redness-relieving eye drops such as Visine® that constrict blood vessels in the eye may cause patients to develop a tolerance or loss of effectiveness and a rebound redness effect. Low-dose brimonidine can lower this risk by selectively constricting veins in the eyes and increasing the availability of oxygen to the surrounding eye tissues, the release said.